In vivo imaging of human cholinergic nerve terminals with (-)-5-(18)F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses.
(-)-5-(18)F-fluoroethoxybenzovesamicol ((18)F-FEOBV) is a vesamicol derivative that binds selectively to the vesicular acetylcholine transporter (VAChT) and has been used in preclinical studies to quantify presynaptic cholinergic nerve terminals. This study presents, to our knowledge, the first-in-human experience with (18)F-FEOBV, including radiation dosimetry, biodistribution, tolerability and safety in human subjects, and brain kinetics and methods for quantitative analysis of (18)F-FEOBV.


METHODS
Whole-body (18)F-FEOBV scans were obtained in 3 healthy human volunteers. Seven additional subjects underwent dynamic brain imaging 0-120, 150-180, and 210-240 min after bolus injection of (18)F-FEOBV. Arterial blood sampling was performed with chromatographic identification of authentic (18)F-FEOBV to determine the arterial plasma input function. Analysis methods included nonlinear least-squares fitting of a 2-tissue-compartmental model, reference tissue modeling, and late single-scan imaging.


RESULTS
No pharmacologic or physiologic changes were observed after intravenous administration of up to 1.3 μg of (18)F-FEOBV. Radiation dosimetry estimates indicate that more than 400 MBq may be administered without exceeding regulatory radiation dose limits. Kinetic analysis showed brain uptake to be relatively high with single-pass extraction of 25%-35%. VAChT binding estimates varied by a factor of greater than 30 between the striatum and cortex. Coefficients of variation in k3 estimates varied from 15% to 30%. Volume of distribution measures yielded a dynamic range of approximately 15 but with little reduction in variability. Reference tissue approaches yielded more stable estimates of the distribution volume ratio (1 + BPND), with coefficients of variation ranging from 20% in the striatum to 6%-12% in cortical regions. The late static distribution of (18)F-FEOBV correlated highly with the distribution volume ratio estimates from reference tissue models (r = 0.993).


CONCLUSIONS
(18)F-FEOBV PET confirms that the tracer binds to VAChT with the expected in vivo human brain distribution. Both reference tissue modeling and late static scanning approaches provide a robust index of VAChT binding.
Department of Radiology, Division of Nuclear Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Myria
M
Petrou
Kirk A
KA
Frey
Michael R
MR
Kilbourn
Peter J H
PJ
Scott
David M
DM
Raffel
Nicolaas I
NI
Bohnen
Martijn L T M
ML
Müller
Roger L
RL
Albin
Robert A
RA
Koeppe
D000293:Adolescent; D000328:Adult; D000368:Aged; D001921:Brain / Q000166:cytology / Q000000981:diagnostic imaging / Q000378:metabolism; D059329:Cholinergic Neurons / Q000166:cytology* / Q000000981:diagnostic imaging* / Q000378:metabolism; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000009:adverse effects / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography / Q000379:methods*; D011849:Radioactive Tracers; D011874:Radiometry; D012449:Safety; D014018:Tissue Distribution; D050494:Vesicular Acetylcholine Transport Proteins / Q000378:metabolism; D055815:Young Adult
D010880:Piperidines; D011849:Radioactive Tracers; D050494:Vesicular Acetylcholine Transport Proteins; C116169:fluoroethoxy-benzovesamicol
18F-FEOBV; PET; VAChT; dementia